Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows

v3.22.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities      
Net loss $ (28,974) $ (61,982) $ (444,116)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Goodwill impairment 386,154
Impairment of other long-lived assets 3,865 1,447 6,985
Depreciation and amortization 59,769 56,096 49,560
Stock-based compensation 33,461 30,977 20,204
Foreign currency transaction loss (gain) 9,090 3,446 (8,718)
Gain from step acquisition (14,400)
Gain from deconsolidation of subsidiary (39,136)
Share in net (profits) losses of associated companies 5,726 (949) 3,939
Revaluation of investments 3,778 (1,301)
Revaluation of contingent consideration (15,805)
Deferred income taxes, net and uncertain tax positions 926 (12,380) (20,299)
Other non-cash items, net (2,778) 2,914 (2,552)
Change in cash attributable to changes in operating assets and liabilities:      
Accounts receivable, net (28,877) (25,003) 29,465
Inventories (87,337) (53) 37,120
Other current assets and prepaid expenses 5,758 (14,976) 10,147
Other non-current assets 4,472 10,460 8,968
Accounts payable 19,614 28,492 (24,534)
Other current liabilities (17,707) 38,952 (10,033)
Deferred revenues 6,577 8,872 (6,398)
Other non-current liabilities (7,827) (14,788) (10,903)
Net cash provided by (used in) operating activities (75,405) 35,824 27,802
Cash flows from investing activities      
Cash paid for business combinations, net of cash acquired (20,553) (29,115)
Purchase of property and equipment (13,635) (24,981) (26,943)
Investments in short-term bank deposits (479,852) (361,000) (27,000)
Proceeds from short-term bank deposits 561,485 129,000 28,300
Proceeds from sale of equity method investment 3,175
Net proceeds from divestitures of subsidiaries and associated companies 1,000
Investments in non-marketable equity securities (69,148) (11,779)
Purchase of intangible assets (6,117) (1,770) (2,070)
Other investing activities 54 (82) 28
Net cash used in investing activities (7,213) (291,165) (52,625)
Cash flows from financing activities      
Proceeds from public offering, net of issuance costs 218,850
Proceeds from exercise of stock options 266 8,055 228
Payment of contingent consideration (2,754)
Other financing activities (281) 406
Net cash provided by (used in) financing activities (2,769) 227,311 228
Effect of exchange rate changes on cash, cash equivalents and restricted cash (7,220) (893) 3,214
Net change in cash, cash equivalents and restricted cash (92,607) (28,923) (21,381)
Cash, cash equivalents and restricted cash, beginning of year 243,293 272,216 293,597
Cash, cash equivalents and restricted cash, end of year 150,686 243,293 272,216
Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:      
Cash and cash equivalents 150,470 243,179 272,092
Restricted cash included in other current assets 216 114 124
Total cash, cash equivalents and restricted cash shown in the statement of cash flows 150,686 243,293 272,216
Supplemental disclosure of cash flow information      
Income taxes, net of tax refunds 12,550 2,418 1,140
Non-cash investing and financing activities:      
Transfer of inventories to fixed assets 9,212 2,673 4,138
Transfer of fixed assets to inventories 123 977 410
Contingent consideration 17,985 37,400
Right-of-use assets obtained in exchange for new operating lease liabilities 12,057 5,955 10,008
Issuance of Common stock under employee stock purchase plan 2,978    
Issuance of shares as part of Origin acquisition (Refer to Note 2) $ 26,636